M Stumvoll - eid, 2003 - informahealthcare.com The role of thiazolidinediones (currently rosiglitazone and pioglitazone) in the treatment of Type
2 diabetes is firmly established. The mechanism of action involves binding to the peroxisome
proliferator-activated receptor-γ, a transcription factor that regulates the expression of ... Cited by 58 - Related articles - BL Direct - All 4 versions
- ►endojournals.org JC Florez, KA Jablonski, MW Sun, N Bayley, SE … - Journal of Clinical …, 2007 - Endocrine Soc Context: The common P12A polymorphism in PPARG (a target for thiazolidinedione
medications) has been consistently associated with type 2 diabetes. ... Objective: We examined
whether PPARG P12A affects progression from impaired glucose tolerance to diabetes, ... Cited by 42 - Related articles - BL Direct - All 7 versions
- ►diabetesjournals.org S Snitker, RM Watanabe, I Ani, AH Xiang, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—The mean changes in S i in the bottom, middle, and top tertiles of S i response were
−0.21 ± 0.57, 0.91 ± 0.26, and 2.58 ± 1.32 min −1 per μU/ml · 10 −4 , respectively. Frequencies
of the Ala/− genotype were 30, 22, and 26% in the same three tertiles (P = 0.77). Analysis ... Cited by 40 - Related articles - BL Direct - All 5 versions
JH Shon, YR Yoon, WS Hong, PM … - …, 2005 - journals2005.pasteur.ac.ir Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation
to the MDR1 genetic polymorphism Objective: Our objective was to evaluate the effect of
itraconazole, a P-glycoprotein inhibitor, on the phar- macokinetics and ... Cited by 34 - Related articles - All 6 versions
ES Kang, SY Park, HJ Kim, CS Kim, CW Ahn, … - Clinical pharmacology …, 2005 - 134.68.189.85 Objective: The aim of this study was to examine the effects of the Pro12Ala polymorphism of the
peroxisome proliferator–activated receptor (PPAR) 2 gene on the response to rosiglitazone in
patients with type 2 diabetes mellitus. Methods: A total of 198 patients with type 2 ... Cited by 33 - Related articles - View as HTML - All 8 versions
JK Wolford, KA Yeatts, SK Dhanjal, MH Black, AH … - Diabetes, 2005 - Am Diabetes Assoc Thiazolidinediones (TZDs) are peroxisome proliferator–activated receptor-γ (PPARG) agonists
used to treat type 2 diabetes. TZDs can also be used to reduce rates of type 2 diabetes in at-risk
individuals. However, a large fraction of TZD-treated patients (30–40%) do not respond to ... Cited by 31 - Related articles - BL Direct - All 5 versions
G Sesti, MA Marini, M Cardellini, A Sciacqua, S … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Of the total patients, 53 (11.1%) were heterozygous for the Arg 972 IRS-1
variant, 1 (0.2%) was homozygous, and the remainder (88.7%) were homozygous for the
wild-type allele. The genotype frequency of the Arg 972 IRS-1 variant was 8.7% among ... Cited by 23 - Related articles - BL Direct - All 5 versions
F Giorgino, L Laviola, A Leonardini - Diabetes research and clinical practice, 2005 - Elsevier Type 2 diabetes mellitus is a chronic metabolic disorder that results from defects in both insulin
secretion and insulin action. Both insulin resistance and β-cell failure are genetically determined
to some extent; however, environmental factors contribute to exacerbate both ... Cited by 15 - Related articles - All 9 versions
A Tönjes, M Stumvoll - Current Opinion in Clinical Nutrition & Metabolic …, 2007 - journals.lww.com Purpose of review To provide a timely update of the literature regarding the role of the Pro12Ala
polymorphism of the peroxisome proliferator-activated receptor g gene in type 2 diabetes and
related phenotypes. Recent findings The adipocyte-specific g2 isoform of peroxisome ... Cited by 7 - Related articles - BL Direct - All 3 versions
